SCHEMBL6485002

SCHEMBL6485002

CCOP(=O)(O)CC(=O)c1cccc(OCc2ccccc2Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 3/20 0.60
NPC1 O15118 2/20 0.60
RAB9A P51151 2/20 0.60
GCK P35557 1/20 0.49
MAOB P27338 4/20 0.47
MAOA P21397 3/20 0.47
NR4A1 P22736 1/20 0.46
NR4A3 Q92570 1/20 0.46
LMNA P02545 2/20 0.44
HPGD P15428 1/20 0.44
SPHK2 Q9NRA0 1/20 0.43
SPHK1 Q9NYA1 1/20 0.43
DDR1 Q08345 1/20 0.41
GPR132 Q9UNW8 1/20 0.41
HDAC8 Q9BY41 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SLC26A4 O43511 1/20 0.41
POLB P06746 1/20 0.40
CASP3 P42574 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490457 0.84 MAOB (0.59) NR4A2MAOBNR4A1NR4A3GPR132
SCHEMBL5733422 0.84 RAB9A (0.51) NPC1RAB9ALMNAHPGDMEN1
SCHEMBL5733382 0.83 NR4A2 (0.64) NR4A2NPC1RAB9AGCKMAOB
SCHEMBL5732744 0.80 MRGPRX4 (0.56) NR4A2NPC1RAB9AMAOBLMNA
SCHEMBL5734272 0.79 SMPD1 (0.53) LMNAMEN1KMT2APOLB
SCHEMBL5733094 0.79 ERCC5 (0.53) NPC1RAB9ALMNAHDAC8MEN1
SCHEMBL5732673 0.79 CES2 (0.51) NPC1RAB9AHPGDHDAC8MEN1
SCHEMBL5734501 0.78 KMT2A (0.46) NR4A2NPC1RAB9AMAOBLMNA
SCHEMBL1436066 0.77 NR4A2 (0.77) NR4A2NPC1RAB9AGCKMAOB
SCHEMBL5732716 0.76 KDM4E (0.45) NPC1RAB9ALMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900336-B2 8-aza-11-deoxy prostaglandin analogues SYNTEX (U.S.A.) LLC (US) 2005-05-31 US disclosed
EP-1409455-A1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-21 EP disclosed
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction SYNTEX (U.S.A.) LLC 2003-06-26 US disclosed
WO-2003008377-A1 PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction PTGER4, FFAR4, PTGER1 NR4A2 166/4885NPC1 918/4885RAB9A 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.